Compare THM & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | NVCT |
|---|---|---|
| Founded | 1978 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 607.2M |
| IPO Year | 2002 | 2021 |
| Metric | THM | NVCT |
|---|---|---|
| Price | $2.16 | $18.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.40 |
| AVG Volume (30 Days) | ★ 525.3K | 155.0K |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $280.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $5.55 |
| 52 Week High | $3.65 | $29.28 |
| Indicator | THM | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 40.16 |
| Support Level | $1.87 | $17.98 |
| Resistance Level | $2.44 | $22.84 |
| Average True Range (ATR) | 0.12 | 1.30 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 26.92 | 20.40 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.